Targeted treatment for advanced salivary gland cancer based on genetic profiling

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial focuses on patients with locally advanced or recurrent/metastatic salivary gland carcinoma, who are categorized into groups based on specific molecular markers such as HER2, NTRK, AR, and TROP-2. Participants receive precision targeted therapies or chemotherapy, and the study evaluates the efficacy and safety of these treatments through metrics like overall response rate (ORR). Additionally, the trial employs multi-omics technology to investigate the heterogeneity of salivary carcinoma and identify biomarkers related to treatment response and prognosis. The study also aims to correlate drug sensitivity findings from ex vivo 3D tumor models with clinical outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with histopathologic diagnosis of salivary gland carcinoma

  * The tumor tissues were subjected to HER2/NTRK/AR/TROP-2 immunohistochemical staining.

    * ECOG physical status 0 or 1 score in the 3 days before the first medication of the study treatment;

      * Age 18 or older - no upper limit;

        * Life expectancy is more than 3 months; ⑥Have at least one measurable lesion according to RECIST1.1 standards; ⑦Women of childbearing age must have a negative pregnancy test within 7 days before the first medication, and agree to receive the necessary contraceptive measures;

          ⑧The patient must have adequate liver, kidney, bone marrow, heart and lung and other organ functions:

          ⑨Understanding and voluntarily signing informed consent prior to performing any research-related evaluation/operation;

          ⑩Ability to comply with research visit schedules and other programmatic requirements.

Exclusion Criteria:

* Known hypersensitivity or delayed anaphylaxis to any agents in this trial;

  * Major surgery had been performed within 4 weeks prior to the start of the study and did not fully recover;

    * Have received a live vaccine within 4 weeks before the start of the study or plan to receive any vaccine during the study period ;

      * To study the occurrence of arterial/venous thrombosis events within 6 months before medication;

        * Major cardiovascular diseases;

          * Is suffering from uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, acute lung disease, interstitial lung disease, cirrhosis, etc.;

            * Is suffering from an active infection that requires systemic treatment;

              * History of active tuberculosis; ⑨ Positive human immunodeficiency virus (HIV) test result; ⑩ Patients with chronic hepatitis B or active hepatitis C. ⑪Conditions that the investigator believes will affect the safety or compliance of the drug therapy in this study ⑫Female/male who is pregnant or breastfeeding or who intends to give birth;

Where it's running

• Fei Ma
  Beijing, Beijing Municipality, China Recruiting
• National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
  Beijing, China Recruiting

Study contacts

• Principal investigator: Jie Zhang — Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology
• Study coordinator: fei Ma
• Email: drmafei@126.com
• Phone: 13910217780

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Abiraterone with dalpiciclib in AR-positive, HER-2 negative salivary gland cancer

  This phase 2 trial tests whether combining abiraterone and dalpiciclib helps people with AR-positive, HER-2 negative salivary gland cancer that has come back or spread.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07815522

• Combining targeted therapies for solid tumors using CDK4/6 inhibitors and anti-VEGF agents

  This study is testing if combining two cancer treatments, Palbociclib and Bevacizumab, can help people with solid tumors like colorectal, breast, and ovarian cancers feel better and respond better to treatment.

  Recruiting at 2 sites Phase 1 Lebanese University · Tripoli, North Lebanon and 1 other locations · NCT06307249

• Multi-omics analysis of progression and tumor biology in head and neck adenoid cystic carcinoma

  We will test whether different tumor biology types in people with metastatic head and neck adenoid cystic carcinoma explain why some cancers grow slowly while others grow faster.

  Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT07507578

• Implantable microdevice drug screening for salivary and head and neck cancers

  This will test whether a tiny implantable microdevice can safely and quickly deliver and screen multiple cancer drugs inside salivary gland and other head and neck tumors in patients scheduled for surgical removal.

  Recruiting at 2 sites Early Phase 1 Brigham and Women's Hospital · Boston, Massachusetts and 1 other locations · NCT05553782

• Evaluating Ivonescimab for advanced salivary gland cancers

  This study is testing a new treatment called Ivonescimab to see if it can help people with advanced salivary gland cancers feel better and improve their health.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06805617

• Comparing treatments for advanced HER2-positive salivary gland cancer

  This study is testing if a new drug called T-DM1 works better than the usual treatment for people with advanced HER2-positive salivary gland cancer, while also looking at another drug for those with lower levels of HER2.

  Recruiting at 143 sites Phase 2 NRG Oncology · Birmingham, Alabama and 153 other locations · NCT05408845

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.